{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:00:03Z","timestamp":1791064803721,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      Obese individuals have high aldosterone levels that may contribute to insulin resistance (\n                      <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                      ) and endothelial dysfunction leading to obesity\u2010induced cardiovascular disease. We conducted a study to evaluate the effect of mineralocorticoid receptor antagonism on\n                      <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                      and endothelial function in obese individuals. This was a placebo\u2010controlled, double\u2010blind, randomized, parallel\u2010group study (\n                      <jats:styled-content style=\"fixed-case\">NCT01406015<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010two non\u2010diabetic, obese subjects [body mass index (\n                      <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\n                      ) 30 to 45\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ] with no other medical problems were randomized to 6\u2009weeks of treatment with spironolactone 50\u2009mg daily or placebo. Insulin sensitivity index (\n                      <jats:styled-content style=\"fixed-case\">ISI<\/jats:styled-content>\n                      ) was assessed by Matsuda method, endothelial function by flow mediated vasodilatation (\n                      <jats:styled-content style=\"fixed-case\">FMD<\/jats:styled-content>\n                      ) of brachial artery and renal plasma perfusion by clearance of para\u2010aminohippurate (\n                      <jats:styled-content style=\"fixed-case\">PAH<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no change in weight,\n                      <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\n                      or plasma potassium during the study period. Treatment with spironolactone led to increases in serum aldosterone (7.6\u2009\u00b1\u20096.6 vs. 3.2\u2009\u00b1\u20091.3\u2009ng\/dl; p\u2009&lt;\u20090.02, post\u2010treatment vs. baseline) and urine aldosterone (11.0\u2009\u00b1\u20097 vs. 4.8\u2009\u00b1\u20092.4\u2009\u00b5g\/g creatinine; p\u2009&lt;\u20090.01) and decreases in systolic blood pressure (116\u2009\u00b1\u200911 vs. 123\u2009\u00b1\u200910\n                      <jats:styled-content style=\"fixed-case\">mmHg<\/jats:styled-content>\n                      ; p\u2009&lt;\u20090.001). There were no changes in these variables in the placebo group. Neither spironolactone nor placebo treatment had a significant effect on\n                      <jats:styled-content style=\"fixed-case\">ISI<\/jats:styled-content>\n                      or other indices of glucose metabolism [insulin resistance by homeostatic model assessment (\n                      <jats:styled-content style=\"fixed-case\">HOMA<\/jats:styled-content>\n                      ), area under the curve for insulin, area under the curve for glucose], brachial artery reactivity or the renal plasma perfusion values. Changes in these variables were similar in two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We conclude that 6\u2009weeks of treatment with spironolactone does not change insulin sensitivity or endothelial function in normotensive obese individuals with no other comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12224","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T07:48:11Z","timestamp":1381736891000},"page":"268-272","source":"Crossref","is-referenced-by-count":47,"title":["Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects"],"prefix":"10.1111","volume":"16","author":[{"given":"R.","family":"Garg","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kneen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. H.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. K.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Available from URL:http:\/\/www.cdc.gov\/obesity\/data\/adult.html. Accessed 20 August 2013."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.23.2847"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1088"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0251"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801483"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3283533955"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0905"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005111196"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1018"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp191"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.748640"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000153800.09920.40"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0944"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0869"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0736"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.03.015"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.36.3.430"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00579.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.9.1462"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht158"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.282"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.6.594"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2158-9"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-010-0126-2"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-924233"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.12-0007"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0393"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1510-8"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.7.2119"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12224","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:17:52Z","timestamp":1761869872000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/dom.12224"],"URL":"https:\/\/doi.org\/10.1111\/dom.12224","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}